218 related articles for article (PubMed ID: 34753803)
1. MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer.
Lee JL; Ekambaram P; Carleton NM; Hu D; Klei LR; Cai Z; Myers MI; Hubel NE; Covic L; Agnihotri S; Krappmann D; Bornancin F; Lee AV; Oesterreich S; McAllister-Lucas LM; Lucas PC
Mol Cancer Res; 2022 Mar; 20(3):373-386. PubMed ID: 34753803
[TBL] [Abstract][Full Text] [Related]
2. MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.
McAuley JR; Bailey KM; Ekambaram P; Klei LR; Kang H; Hu D; Freeman TJ; Concel VJ; Hubel NE; Lee JL; Klei HB; Cheng J; Sekar P; Bridwell RE; Covic L; Lucas PC; McAllister-Lucas LM
Oncogene; 2019 Dec; 38(49):7384-7398. PubMed ID: 31420608
[TBL] [Abstract][Full Text] [Related]
3. The CARMA3-Bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer.
Ekambaram P; Lee JL; Hubel NE; Hu D; Yerneni S; Campbell PG; Pollock N; Klei LR; Concel VJ; Delekta PC; Chinnaiyan AM; Tomlins SA; Rhodes DR; Priedigkeit N; Lee AV; Oesterreich S; McAllister-Lucas LM; Lucas PC
Cancer Res; 2018 Mar; 78(5):1225-1240. PubMed ID: 29259013
[TBL] [Abstract][Full Text] [Related]
4. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
5. Transferrin Coated d-penicillamine-Au-Cu Nanocluster PLGA Nanocomposite Reverses Hypoxia-Induced EMT and MDR of Triple-Negative Breast Cancers.
Shome R; Ghosh SS
ACS Appl Bio Mater; 2021 Jun; 4(6):5033-5048. PubMed ID: 35007052
[TBL] [Abstract][Full Text] [Related]
6. Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT.
Zhu Y; Tao Z; Chen Y; Lin S; Zhu M; Ji W; Liu X; Li T; Hu X
Breast Cancer Res Treat; 2022 May; 193(1):65-81. PubMed ID: 35254603
[TBL] [Abstract][Full Text] [Related]
7. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
[TBL] [Abstract][Full Text] [Related]
8. Propolin G-Suppressed Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer Cells via Glycogen Synthase Kinase 3β-Mediated Snail and HDAC6-Regulated Vimentin Degradation.
Pai JT; Chen XH; Leu YL; Weng MS
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163593
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis.
Sinha S; Sharma S; Sharma A; Vora J; Shrivastava N
Phytomedicine; 2021 Apr; 84():153492. PubMed ID: 33640782
[TBL] [Abstract][Full Text] [Related]
10. Ancient Origin of the CARD-Coiled Coil/Bcl10/MALT1-Like Paracaspase Signaling Complex Indicates Unknown Critical Functions.
Staal J; Driege Y; Haegman M; Borghi A; Hulpiau P; Lievens L; Gul IS; Sundararaman S; Gonçalves A; Dhondt I; Pinzón JH; Braeckman BP; Technau U; Saeys Y; van Roy F; Beyaert R
Front Immunol; 2018; 9():1136. PubMed ID: 29881386
[TBL] [Abstract][Full Text] [Related]
11. NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling.
Zhang J; Shao X; Sun H; Liu K; Ding Z; Chen J; Fang L; Su W; Hong Y; Li H; Li H
Oncotarget; 2016 Sep; 7(38):61036-61053. PubMed ID: 27506933
[TBL] [Abstract][Full Text] [Related]
12. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
13. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Nam SJ; Lee JE
Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
[TBL] [Abstract][Full Text] [Related]
14. Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
Tang YH; Rockstroh A; Sokolowski KA; Lynam LR; Lehman M; Thompson EW; Gregory PA; Nelson CC; Volpert M; Hollier BG
Breast Cancer Res; 2022 Jan; 24(1):8. PubMed ID: 35078508
[TBL] [Abstract][Full Text] [Related]
15. MALT1 activation by TRAF6 needs neither BCL10 nor CARD11.
Bardet M; Seeholzer T; Unterreiner A; Woods S; Krappmann D; Bornancin F
Biochem Biophys Res Commun; 2018 Nov; 506(1):48-52. PubMed ID: 30336982
[TBL] [Abstract][Full Text] [Related]
16. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells.
Taliaferro-Smith L; Oberlick E; Liu T; McGlothen T; Alcaide T; Tobin R; Donnelly S; Commander R; Kline E; Nagaraju GP; Havel L; Marcus A; Nahta R; O'Regan R
Oncotarget; 2015 Mar; 6(7):4757-72. PubMed ID: 25749031
[TBL] [Abstract][Full Text] [Related]
17. Activation of GPER suppresses epithelial mesenchymal transition of triple negative breast cancer cells via NF-κB signals.
Chen ZJ; Wei W; Jiang GM; Liu H; Wei WD; Yang X; Wu YM; Liu H; Wong CK; Du J; Wang HS
Mol Oncol; 2016 Jun; 10(6):775-88. PubMed ID: 26842883
[TBL] [Abstract][Full Text] [Related]
18. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
[TBL] [Abstract][Full Text] [Related]
19. DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer.
Matsunuma R; Chan DW; Kim BJ; Singh P; Han A; Saltzman AB; Cheng C; Lei JT; Wang J; Roberto da Silva L; Sahin E; Leng M; Fan C; Perou CM; Malovannaya A; Ellis MJ
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E11978-E11987. PubMed ID: 30498031
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.
Hoang VT; Matossian MD; La J; Hoang K; Ucar DA; Elliott S; Burks HE; Wright TD; Patel S; Bhatt A; Phamduy T; Chrisey D; Buechlein A; Rusch DB; Nephew KP; Anbalagan M; Rowan B; Cavanaugh JE; Flaherty PT; Miele L; Collins-Burow BM; Burow ME
J Cell Biochem; 2021 Aug; 122(8):835-850. PubMed ID: 33876843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
